Changes in Persistent Asthma Care and Outcomes From 2006 to 2016 in France.
Adolescent
Adrenal Cortex Hormones
/ therapeutic use
Adrenergic beta-Agonists
/ therapeutic use
Adult
Anti-Asthmatic Agents
/ therapeutic use
Asthma
/ drug therapy
Female
France
/ epidemiology
Hospitalization
Humans
Leukotriene Antagonists
/ therapeutic use
Male
Omalizumab
/ therapeutic use
Patient Acceptance of Health Care
Treatment Outcome
Young Adult
Asthma
Care
Claims data
Outcomes
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
Historique:
received:
10
09
2018
revised:
15
02
2019
accepted:
15
02
2019
pubmed:
6
3
2019
medline:
8
9
2020
entrez:
6
3
2019
Statut:
ppublish
Résumé
Changes in asthma care need to be documented at arrival of biotherapies. To characterize changes in asthma care and outcomes in patients with persistent asthma. Repeated transversal analyses were conducted on a historical cohort using the French national claims data over 10 years. Patients aged 18 to 40 years with either 1 or more (any-use population) or 4 or more (high-use population) yearly dispensings of controller therapy were selected. Clinical and demographic features were characterized, and comparisons were made between 2006 and 2016 to assess temporal changes in asthma therapy, health care resource utilization, and outcomes. In 2016, prevalent use of controller therapy was 5.2% (any-use population) and 0.8% (high-use population) of the population aged 18 to 40 years. In the any-use population, the use of long-acting β Changes in persistent asthma care included replacement of inhaled corticosteroids by fixed-dose combinations, decreased use of long-acting β
Sections du résumé
BACKGROUND
Changes in asthma care need to be documented at arrival of biotherapies.
OBJECTIVES
To characterize changes in asthma care and outcomes in patients with persistent asthma.
METHODS
Repeated transversal analyses were conducted on a historical cohort using the French national claims data over 10 years. Patients aged 18 to 40 years with either 1 or more (any-use population) or 4 or more (high-use population) yearly dispensings of controller therapy were selected. Clinical and demographic features were characterized, and comparisons were made between 2006 and 2016 to assess temporal changes in asthma therapy, health care resource utilization, and outcomes.
RESULTS
In 2016, prevalent use of controller therapy was 5.2% (any-use population) and 0.8% (high-use population) of the population aged 18 to 40 years. In the any-use population, the use of long-acting β
CONCLUSIONS
Changes in persistent asthma care included replacement of inhaled corticosteroids by fixed-dose combinations, decreased use of long-acting β
Identifiants
pubmed: 30836232
pii: S2213-2198(19)30202-8
doi: 10.1016/j.jaip.2019.02.025
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-Agonists
0
Anti-Asthmatic Agents
0
Leukotriene Antagonists
0
Omalizumab
2P471X1Z11
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1858-1867Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.